Mirae Asset Sharekhan

DOWNLOAD SHAREKHAN APP

Mirae Asset Sharekhan

OPEN DEMAT ACCOUNT

LOGIN / TRADE OPEN ACCOUNT

Follow Us :

Sharekhan

BUY NOW Buy Vivanza Biosciences Ltd Stock

Open Free Demat and Trading account in 15 minutes

Overview
Market Data
Market Depth
Option Chain
News
Fundamental
Shareholding Pattern
Corporate Action
Peers
Company Info
FAQ’s

Home Stock Vivanza Biosciences Ltd

Wed 4/03/2026,16:1:0

NSE

BSE

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 1.96

Previous Close

₹ 1.96

Volume

24191

Mkt Cap ( Rs. Cr)

₹7.92

High

₹ 1.98

Low

₹ 1.96

52 Week High

₹ 2.94

52 Week Low

₹ 1.90

Book Value Per Share

₹ 1.20

Dividend Yield

0.00

Face Value

₹ 1.00

What’s Your Call?

Collective community sentiment on Vivanza Biosciences Ltd

Your Vote -

Buy

50.00%

Hold

25.00%

Sell

25.00%

50.00%

4 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Vivanza Biosciences Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

Vivanza Biosciences Q3 net profit zooms 300.00% at Rs 0.16 cr

12 Feb 2026, 3:50PM The company reported standalone net profit of Rs 0.16 crore for the quarter ended December 31, 2025 as compared to Rs 0.04 crore in the same period la
Vivanza Biosciences - Non-Applicability Of Statement Of Deviation Or Variation Under Regulation 32 Of SEBI (Listing Obligatio

12 Feb 2026, 3:36PM Pursuant to regulation 32 of SEBI (Listing Obligation and Disclosure Requirements, 2015, read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated 24th
Vivanza Biosciences - Outcome Of The Board Meeting And Submission Of Un-Audited Financial Results For The Quarter And Nine Mo

12 Feb 2026, 3:23PM Pursuant to Regulation 30 and Regulation 33 of SEBI (LODR) Regulations, 2015 this is to inform you that the Board of Directors at its meeting held on
Vivanza Biosciences - Board Meeting Outcome for Outcome Of The Board Meeting And Submission Of Un-Audited Financial Results F

12 Feb 2026, 3:11PM Pursuant to Regulation 30 and Regulation 33 of the SEBI (LODR) Regulations, 2015, this is to inform you that the Board of Directors at its meeting hel
Vivanza Biosciences - Board Meeting Intimation for Consideration Of Financial Result For The Quarter And Nine Months Ended 31

5 Feb 2026, 3:46PM Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 ,inter alia, to consider
Vivanza Biosciences has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2025

20 Jan 2026, 5:50PM As of December 2025, 20.02% is owned by Indian Promoters and 79.98% by Public. <p align=justify> Top two Promoters holding highest number of shares of
Vivanza Biosciences - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

2 Jan 2026, 5:51PM We hereby enclose the Confirmation Certificate Under regulation 74(5) of SEBI (Depositories and participants) Regulations, 2018 received from Purva Sh
Vivanza Biosciences - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association

18 Dec 2025, 2:35PM Pursuant to Regulation 30(2) of SEBI, LODR Regulations, 2015 and SEBI Circular Dated November 11, 2024 the members have approved, by Special Resolutio
Vivanza Biosciences - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report

17 Dec 2025, 6:01PM Voting Results and Scrutinizer Report of Postal Ballot
Vivanza Biosciences - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot

17 Dec 2025, 5:58PM Proceedings/Outcome of Postal Ballot

Key fundamentals

Evaluate the intrinsic value of Vivanza Biosciences Ltd stock

Name	March-25	March-24	March-23	March-22	March-21
Assets	10.113	7.9781	10.9623	5.5128	3.5404
Liabilities	10.113	7.9781	10.9623	5.5128	3.5404
Equity	4	4	4	4	4
Gross Profit	-0.3634	0.7998	0.7212	0.049	0.1259
Net Profit	-0.6951	0.3174	0.5691	0.4636	0.0998
Cash From Operating Activities	-2.4688	1.7835	0.1607	-0.6771	-3.0778
NPM(%)	-23.62	2.2	4	5.06	1.08
Revenue	2.9428	14.4132	14.2071	9.1475	9.2233
Expenses	3.3062	13.6134	13.4859	9.0984	9.0973
ROE(%)	-14.45	6.59	11.83	9.64	2.07

Shareholding Pattern

Corporate Action

XD-Date	Dividend-Amount	Dividend-%	Dividend Yield(%GE)	Price on that day

From Year	To Year	Class of Share	Authorized Capital(Crores)	Issued Capital(Crores)	Paid Up Shares(NOS)	Paid Up Face Value	Paid Up Capital(Crores)
2024	2025	Equity Share	4.00	4.00	40000000.00	1	4.00
2023	2024	Equity Share	4.00	4.00	40000000.00	1	4.00
2022	2023	Equity Share	4.00	4.00	40000000.00	1	4.00
2021	2022	Equity Share	4.00	4.00	4000000.00	10	4.00
2020	2021	Equity Share	4.00	4.00	4000000.00	10	4.00
2019	2020	Equity Share	4.00	4.00	4000000.00	10	4.00
2018	2019	Equity Share	4.00	4.00	4000000.00	10	4.00
2017	2018	Equity Share	4.00	4.00	4000000.00	10	4.00
2016	2017	Equity Share	4.00	4.00	4000000.00	10	4.00
2015	2016	Equity Share	4.00	0.19	188000.00	10	0.19
2014	2015	Equity Share	4.00	3.76	3760000.00	10	3.76
2013	2014	Equity Share	4.00	3.76	3760000.00	10	3.76
2012	2013	Equity Share	4.00	3.76	3760000.00	10	3.76
2011	2012	Equity Share	4.00	3.76	3760000.00	10	3.76
2010	2011	Equity Share	4.00	3.76	3760000.00	10	3.76
2009	2010	Equity Share	4.00	3.76	3760000.00	10	3.76
2001	2002	Equity Share	4.00	3.76	3760000.00	10	3.76
1999	2000	Equity Share	4.00	3.76	3760000.00	10	3.76
1996	1999	Equity Share	4.00	3.76	3760000.00	10	3.76
1995	1996	Equity Share	4.00	3.76	3760000.00	10	3.76

Announcement Date	Price	Bonus Ratio	Record Date

Fund	Market Value(CR)	% Hold
No Records Found

Peers

Other companies within the same industry or sector that are comparable to Vivanza Biosciences Ltd

Company	Price	Price (% change)	pe(x)	EV/EBITDA(x)	ROE(%)	ROCE(%)
Albert David Ltd	688.00	0.28	41.25	1.13	301.39	0.72
Lotus Eye Hospital and Institute Ltd	108.65	0.56	351.16	4.12	3.55	0.00
Bharat Immunological and Biologicals Corporation Ltd	16.93	-1.63	0.00	8.55	-39.50	0.00
Astec Lifesciences Ltd	635.00	1.01	0.00	3.88	-604.75	0.00

Company Info

Ivee Injectaa Limited is engaged in the manufacture of Large Volume Parenterals (LVPs) and diversifying into manufacture of Small Volume Parenterals (SVPs) and other allied activities. The company is listed on Bombay Stock Exchange. 2012 -Change of Share Registrar and Transfer Agent from M/s. Link Intime India Private Limited to M/s. Purva Sharegistry India Private Limited. 2015 -The name of the company has been changed from Ivee Injectaa Ltd. to Vivanza Biosciences Ltd. 2023 -The Company has splits its face value from Rs. 10/- to Rs. 1/-.

Ivee Injectaa Limited is engaged in the manufacture of Large Volume Parenterals (LVPs) and diversifying into manufacture of Small Volume Parenterals (SVPs) and other allied activities. The company is listed on Bombay Stock Exchange. 2012 -Change of Share Registrar and Transfer Agent from M/s. Link Intime India Private Limited to M/s. Purva Sharegistry India Private Limited. 2015 -The name of the company has been changed from Ivee Injectaa Ltd. to Vivanza Biosciences Ltd. 2023 -The Company has splits its face value from Rs. 10/- to Rs. 1/-.

Read More

Parent Organisation

Vivanza Biosciences Ltd.

Founded

06/03/1982

Managing Director

Mr.J A Mehta

NSE Symbol

FAQ

The current price of Vivanza Biosciences Ltd is ₹ 1.98.

The 52-week high for Vivanza Biosciences Ltd is

The market capitalization of Vivanza Biosciences Ltd is currently ₹ 7.92. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Vivanza Biosciences Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Vivanza Biosciences Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Vivanza Biosciences Ltd shares.

The CEO of Vivanza Biosciences Ltd is Mr.J A Mehta, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT